Skip to main content
Erschienen in: Journal of Neurology 12/2006

01.12.2006 | ORIGINAL COMMUNICATION

Reasons to withhold intra-arterial thrombolysis in clinical practice

verfasst von: J. Isenegger, MD, K. Nedeltchev, MD, M. Arnold, MD, U. Fischer, G. Schroth, MD, L. Remonda, MD, H.P. Mattle

Erschienen in: Journal of Neurology | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

In selected stroke centers intra-arterial thrombolysis (IAT) is used for the treatment of acute stroke patients presenting within 6 hours of symptom onset. However, data about eligibility of acute stroke patients for IAT in clinical practice are very scarce.

Methods

We collected prospectively data on indications advising for or against IAT of 230 consecutive stroke patients in a tertiary stroke center.

Results

76 patients (33.0%) presented within 3 hours, 69 (30%) between 3 and 6 hours of symptom onset and 85 (37%) later than 6 hours. Arteriography was performed in 71 patients (31%) and IAT in 46 (20%). In 11 patients no or only peripheral branch occlusions were seen on arteriography and therefore IAT was not performed. In 9 patients the ICA was occluded and barred IAT and in five anatomical or technical difficulties made IAT impossible. 72 patients presenting within 6 hours did not undergo arteriography and thrombolysis, mostly because of mild (n = 44) or rapidly improving neurological deficits (n = 13). Other reasons to withhold IAT were CT and/or clinical findings suggesting lacunar stroke due to small vessel occlusion (n = 7), limiting comorbidty (n = 7) and baseline international normalized ratio > 1.7 (n = 1).

Conclusions

A third of the patients underwent diagnostic arteriography and one fifth received IAT. The most important reasons to withhold thrombolysis were presentation beyond the 6 hours time window and mild or rapidly improving symptoms.
Literatur
1.
Zurück zum Zitat Arnold M, Nedeltchev K, Mattle HP, Loher TJ, Stepper F, Schroth G, Brekenfeld C, Sturzenegger M, Remonda L (2003) Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry 74:739–742PubMedCrossRef Arnold M, Nedeltchev K, Mattle HP, Loher TJ, Stepper F, Schroth G, Brekenfeld C, Sturzenegger M, Remonda L (2003) Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry 74:739–742PubMedCrossRef
2.
Zurück zum Zitat Arnold M, Nedeltchev K, Brekenfeld C, Fischer U, Remonda L, Schroth G, Mattle H (2004) Outcome of acute stroke patients without visible occlusion on early arteriography. Stroke 35:1135–1140PubMedCrossRef Arnold M, Nedeltchev K, Brekenfeld C, Fischer U, Remonda L, Schroth G, Mattle H (2004) Outcome of acute stroke patients without visible occlusion on early arteriography. Stroke 35:1135–1140PubMedCrossRef
3.
Zurück zum Zitat Arnold M, Nedeltchev K, Schroth G, Baumgartner RW, Remonda L, Loher TJ, Stepper F, Sturzenegger M, Schuknecht B, Mattle HP (2004) Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry 75:857–862PubMedCrossRef Arnold M, Nedeltchev K, Schroth G, Baumgartner RW, Remonda L, Loher TJ, Stepper F, Sturzenegger M, Schuknecht B, Mattle HP (2004) Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry 75:857–862PubMedCrossRef
4.
Zurück zum Zitat Arnold M, Schroth G, Nedeltchev K, Loher T, Remonda L, Stepper F, Sturzenegger M, Mattle HP (2002) Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 33:1828–1833PubMedCrossRef Arnold M, Schroth G, Nedeltchev K, Loher T, Remonda L, Stepper F, Sturzenegger M, Mattle HP (2002) Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 33:1828–1833PubMedCrossRef
5.
Zurück zum Zitat Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015–1020PubMed Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015–1020PubMed
6.
Zurück zum Zitat Brott T, Adams HP Jr., Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870PubMed Brott T, Adams HP Jr., Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870PubMed
7.
Zurück zum Zitat Buchan AM, Barber PA, Newcommon N, Karbalai HG, Demchuk AM, Hoyte KM, Klein GM, Feasby TE (2000) Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 54:679–684PubMed Buchan AM, Barber PA, Newcommon N, Karbalai HG, Demchuk AM, Hoyte KM, Klein GM, Feasby TE (2000) Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 54:679–684PubMed
8.
Zurück zum Zitat Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282:2003–2011PubMedCrossRef Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282:2003–2011PubMedCrossRef
9.
Zurück zum Zitat Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss WD (1998) Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29:1544–1549PubMed Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss WD (1998) Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 29:1544–1549PubMed
10.
Zurück zum Zitat Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV (2001) Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 58:2009–2013PubMedCrossRef Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV (2001) Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 58:2009–2013PubMedCrossRef
11.
Zurück zum Zitat Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36:66–73PubMedCrossRef Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group (2005) The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36:66–73PubMedCrossRef
12.
Zurück zum Zitat Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, ATLANTIS Trials Investigators; ECASS Trials Investigators, NINDS rt-PA Study Group Investigators (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768–774PubMedCrossRef Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, ATLANTIS Trials Investigators; ECASS Trials Investigators, NINDS rt-PA Study Group Investigators (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768–774PubMedCrossRef
13.
Zurück zum Zitat Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL (2003) Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 34:1106–1113PubMedCrossRef Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL (2003) Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 34:1106–1113PubMedCrossRef
14.
Zurück zum Zitat Katzan IL, Graber TM, Furlan AJ, Sundararajan S, Sila CA, Houser G, Landis DM. Cuyahoga (2003) County Operation Stroke Speed of Emergency Department Evaluation and Compliance With National Institutes of Neurological Disorders and Stroke Time Targets. Stroke 36:6 Katzan IL, Graber TM, Furlan AJ, Sundararajan S, Sila CA, Houser G, Landis DM. Cuyahoga (2003) County Operation Stroke Speed of Emergency Department Evaluation and Compliance With National Institutes of Neurological Disorders and Stroke Time Targets. Stroke 36:6
15.
Zurück zum Zitat Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, Happola O, Tiainen M, Haapaniemi E, Kuisma M, Kaste M (2003) Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 34:1443–1449PubMedCrossRef Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, Happola O, Tiainen M, Haapaniemi E, Kuisma M, Kaste M (2003) Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 34:1443–1449PubMedCrossRef
16.
Zurück zum Zitat Nedeltchev K, Arnold M, Brekenfeld C, Isenegger J, Remonda L, Schroth G, Mattle HP (2003) Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke 34:1230–1234PubMedCrossRef Nedeltchev K, Arnold M, Brekenfeld C, Isenegger J, Remonda L, Schroth G, Mattle HP (2003) Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke 34:1230–1234PubMedCrossRef
17.
Zurück zum Zitat Nedeltchev K, Brekenfeld C, Remonda L, Ozdoba CH, Do D, Arnold M, Mattle HP, Schroth G. Stenting Of The Internal Carotid Artery in Acute Stroke: Preliminary Results Of 25 Patients. Radiology, in press Nedeltchev K, Brekenfeld C, Remonda L, Ozdoba CH, Do D, Arnold M, Mattle HP, Schroth G. Stenting Of The Internal Carotid Artery in Acute Stroke: Preliminary Results Of 25 Patients. Radiology, in press
18.
Zurück zum Zitat Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, Stewart-Wynne EG, Rosen D, McNeil JJ, Bladin CF, Chambers BR, Herkes GK, Young D, Donnan GA (2005) Results of a Multicentre, Randomised Controlled Trial of Intra-Arterial Urokinase in the Treatment of Acute Posterior Circulation Ischaemic Stroke.Cerebrovasc Dis. 20(1):12–17PubMedCrossRef Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, Stewart-Wynne EG, Rosen D, McNeil JJ, Bladin CF, Chambers BR, Herkes GK, Young D, Donnan GA (2005) Results of a Multicentre, Randomised Controlled Trial of Intra-Arterial Urokinase in the Treatment of Acute Posterior Circulation Ischaemic Stroke.Cerebrovasc Dis. 20(1):12–17PubMedCrossRef
19.
Zurück zum Zitat Mattle HP, Kappeler L, Arnold M, Fischer U, Nedeltchev K, Remonda L, Jakob SM, Schroth G (2005) Blood pressure and vessel recanalization in the first hours after ischemic stroke. Stroke 36:264–268PubMedCrossRef Mattle HP, Kappeler L, Arnold M, Fischer U, Nedeltchev K, Remonda L, Jakob SM, Schroth G (2005) Blood pressure and vessel recanalization in the first hours after ischemic stroke. Stroke 36:264–268PubMedCrossRef
20.
Zurück zum Zitat Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG (2001) Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32:1832–1840PubMed Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG (2001) Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32:1832–1840PubMed
21.
Zurück zum Zitat Schmulling S, Grond M, Rudolf J, Heiss WD (2000) One-year follow-Up in acute stroke patients treated with rtPA in clinical routine. Stroke 31:1552–1554PubMed Schmulling S, Grond M, Rudolf J, Heiss WD (2000) One-year follow-Up in acute stroke patients treated with rtPA in clinical routine. Stroke 31:1552–1554PubMed
22.
Zurück zum Zitat The National Institute of Neurological Disorders, Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587CrossRef The National Institute of Neurological Disorders, Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587CrossRef
23.
Zurück zum Zitat van Swieten JC, Koudstaal PJ, Visser MC, Schouten JH, von Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607PubMed van Swieten JC, Koudstaal PJ, Visser MC, Schouten JH, von Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607PubMed
24.
Zurück zum Zitat Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC (2000) Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 31:77–81 Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC (2000) Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 31:77–81
25.
Zurück zum Zitat Weber J, Remonda L, Mattle HP, Koerner U, Baumgartner RW, Sturzenegger M, Ozdoba C, Koerner F, Schroth G (1998) Selective intra-arterial fibrinolysis of acute central retinal artery occlusion. Stroke 29:2076–2079PubMed Weber J, Remonda L, Mattle HP, Koerner U, Baumgartner RW, Sturzenegger M, Ozdoba C, Koerner F, Schroth G (1998) Selective intra-arterial fibrinolysis of acute central retinal artery occlusion. Stroke 29:2076–2079PubMed
Metadaten
Titel
Reasons to withhold intra-arterial thrombolysis in clinical practice
verfasst von
J. Isenegger, MD
K. Nedeltchev, MD
M. Arnold, MD
U. Fischer
G. Schroth, MD
L. Remonda, MD
H.P. Mattle
Publikationsdatum
01.12.2006
Erschienen in
Journal of Neurology / Ausgabe 12/2006
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-006-0220-1

Weitere Artikel der Ausgabe 12/2006

Journal of Neurology 12/2006 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.